Join the 'Lymphoma' group to help and get support from people like you.

Lymphoma Blog

Related terms: Cancer, Lymphoma

Screening Test Approved for Viruses That Cause Blood Cancer

Posted 7 days ago by Drugs.com

THURSDAY, Dec. 11, 2014 – A new screening test to detect Human T-Cell Lymphotropic viruses that cause a rare blood cancer has been approved by the U.S. Food and Drug Administration. The viruses, abbreviated HTLV-I/II, cause diseases such as adult T-cell leukemia/lymphoma (blood cancer) and myelopathy (inflammation of spinal cord nerves) , the FDA said in a news release. HTLV can be transmitted via breastfeeding, unprotected sex or blood transfusion. The newly approved test – MP Diagnostics HTLV Blot 2.4 – is meant to supplement existing screening for the viruses, the FDA said. The diagnostic also can differentiate between the two types, HTLV-I or HTLV-II. Many people infected with HTLV may not be aware of its presence, since the virus does not always trigger symptoms. An infected person can transmit the virus without showing any signs or symptoms, the agency said. The new test is ... Read more

Related support groups: Leukemia, Lymphoma, Diagnosis and Investigation

Mutations Linked to Blood Cancers Rise With Age, Study Shows

Posted 22 Oct 2014 by Drugs.com

WEDNESDAY, Oct. 22, 2014 – Blood cell mutations linked to the blood cancers leukemia and lymphoma increase as people get older, according to a new study. Researchers analyzed blood samples from nearly 3,000 Americans, ages 10 to 90, and found the mutations in less than 1 percent of those ages 40 to 49. By the time people are between 70 and 79, 5 percent will have blood cell mutations, according to the study. For people between 80 and 89, more than 6 percent will be affected, the researchers found. Cell mutations accumulate as people age, and most are harmless, according to the researchers. They said that having these blood cell mutations associated with leukemia and lymphoma doesn't mean a person will develop these blood cancers. In fact, the diseases occur in less than 0.1 percent of elderly Americans, the researchers noted. "But it's quite striking how many people over age 70 have ... Read more

Related support groups: Leukemia, Lymphoma

Lymphoma Treatment May Harm, Halt Men's Sperm Production

Posted 26 Jul 2014 by Drugs.com

FRIDAY, July 25, 2014 (HealthDay – Treatment for lymphoma may lower men's fertility, new research indicates. Both Hodgkin lymphoma and non-Hodgkin lymphoma, which are cancers of the body's white blood cells, often affect young people who are still in their reproductive years. For men, treatment for these cancers can harm or halt sperm production. Although most men regain their fertility within two years of treatment, the researchers cautioned that men should be counseled about the possibility of this significant side effect before treatment begins. "While many men can look forward to their fertility returning after treatment is over, not all will be so fortunate," Dr. Rebecca Sokol, president of the American Society for Reproductive Medicine, said in a society news release. "It is imperative that prior to the initiation of therapy, counseling and sperm preservation be made available to ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma

FDA Approves Zydelig (idelalisib) for CLL and Lymphoma

Posted 23 Jul 2014 by Drugs.com

July 23, 2014 – The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic leukemia (CLL) has returned (relapsed). Used in combination with Rituxan (rituximab), Zydelig is to be used in patients for whom Rituxan alone would be considered appropriate therapy due to other existing medical conditions (co-morbidities). Zydelig is the fifth new drug with breakthrough therapy designation to be approved by the FDA and the third drug with this designation approved to treat CLL. The FDA is also granting Zydelig accelerated approval to treat patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and relapsed small lymphocytic lymphoma (SLL), another type of non-Hodgkin lymphoma. Zydelig is intended to be used in patients who ... Read more

Related support groups: Leukemia, Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

Zydelig Approved for Three Types of Blood Cancer

Posted 23 Jul 2014 by Drugs.com

WEDNESDAY, July 23, 2014 – Zydelig (idelalisib) has been approved by the U.S. Food and Drug Administration to treat relapsed forms of blood cancer, including chronic lymphocytic leukemia (CLL), follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL), the FDA said Wednesday in a news release. The approval for the three forms of blood cancer covers instances when the cancer returns despite treatment with at least one other therapy, the agency said. The drug's label will include a boxed warning that the medication could cause liver toxicity, diarrhea, high blood sugar, elevated liver enzymes, high blood triglycerides [a blood fat] and inflammation of the colon (colitis). Other side effects noted during clinical testing included fever, fatigue, nausea, cough, pneumonia, abdominal pain, chills and rash. Zydelig is marketed by Gilead Sciences, based in Foster City, ... Read more

Related support groups: Lymphoma, Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma, Follicular Lymphoma

FDA Approves Beleodaq (belinostat) for Peripheral T-Cell Lymphoma

Posted 3 Jul 2014 by Drugs.com

July 3, 2014 – The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. PTCL comprises a diverse group of rare diseases in which lymph nodes become cancerous. In 2014, the National Cancer Institute estimates that 70,800 Americans will be diagnosed with NHL and 18,990 will die. PTCL represents about 10 to 15 percent of NHLs in North America. Beleodaq works by stopping enzymes that contribute to T-cells, a type of immune cell, becoming cancerous. It is intended for patients whose disease returned after treatment (relapsed) or did not respond to previous treatment (refractory). “This is the third drug that has been approved since 2009 for the treatment of peripheral T-c ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

Beleodaq Approved for Aggressive non-Hodgkin Lymphoma

Posted 3 Jul 2014 by Drugs.com

THURSDAY, July 3, 2014 – Beleodaq (belinostat) has been approved by the U.S. Food and Drug Administration to treat peripheral T-Cell lymphoma (PTCL), a rare and aggressive form of non-Hodgkin lymphoma (cancer of the lymph nodes). Some 70,800 Americans will be diagnosed with non-Hodgkin lymphoma this year, of which up to 15 percent will be PTCL, according to U.S. National Cancer Institute estimates. Beleodaq is designed to inhibit immune cells called T-cells from becoming cancerous, the FDA explained Thursday in a news release. The drug is intended for people whose cancer has returned or who didn't respond to a prior therapy, the agency said. Beleodaq's safety and effectiveness were evaluated in clinical studies involving 129 people with PTCL. All were treated with the newly approved drug, and about 26 percent had their cancer disappear or shrink, the FDA said. The most common side ... Read more

Related support groups: Cancer, Lymphoma, Non-Hodgkin's Lymphoma, Peripheral T-cell Lymphoma

Experimental Drug May Boost Leukemia Survival, Without Chemo

Posted 12 Mar 2014 by Drugs.com

WEDNESDAY, March 12, 2014 – An experimental drug may extend the lives of people with certain hard-to-treat forms of leukemia and lymphoma – without the need for traditional chemotherapy, according to two studies released Wednesday. The drug, called idelalisib, targets a specific enzyme on white blood cells known as B cells. Researchers found that for people with certain forms of recurrent blood cancers, the drug substantially extended the time that patients lived with no tumor progression. One of the trials, of patients with chronic lymphocytic leukemia (CLL), was stopped early because the benefits of idelalisib over standard treatment became so clear. The drug is now up for expedited review by the U.S. Food and Drug Administration (FDA), for possible approval. A cancer researcher not involved in either trial called the CLL results "fantastic." If idelalisib is approved, "I think ... Read more

Related support groups: Leukemia, Lymphoma, Chronic Lymphocytic Leukemia (CLL)

Study: Pollen Allergies May Raise Risk for Blood Cancers in Women

Posted 4 Dec 2013 by Drugs.com

WEDNESDAY, Dec. 4, 2013 – Women with pollen allergies may be at increased risk for blood cancers such as leukemia and lymphoma, a new study suggests. Researchers did not uncover the same link in men. This suggests there is something unique in women that causes chronic allergy-related stimulation of the immune system to increase vulnerability to the development of blood cancers, the study authors said. The study included 66,000 people, aged 50 to 76, who were followed for an average of eight years. During the follow-up period, 681 people developed a blood cancer. These people were more likely to be male, to have two or more first-degree relatives with a history of leukemia or lymphoma, to be less active and to rate their health status as poor. Among women, however, a history of allergies to plants, grass and trees was significantly associated with a higher risk of blood cancers. The ... Read more

Related support groups: Allergies, Leukemia, Lymphoma

Lymphoma Risk Varies for Celiac Disease Patients

Posted 5 Aug 2013 by Drugs.com

MONDAY, Aug. 5 – Celiac disease patients with ongoing intestinal damage have a higher risk for lymphoma than those with healed intestines, a new study finds. The intestinal damage in people with celiac disease is caused by a reaction to eating gluten, which is found in wheat, barley and rye. After diagnosis, many patients switch to a gluten-free diet. Patients often are followed up on to assess the effects that dietary changes and treatment have on intestinal healing. Lymphoma is a type of blood cancer that begins in the lymph system, and can eventually spread to other parts of the body. This study included more than 7,600 people with celiac disease who had follow-up intestinal biopsies six months to five years after their diagnosis, and were then followed for roughly nine years. At the time of their follow-up biopsy, 57 percent of the patients had healed intestines while 43 percent ... Read more

Related support groups: Celiac Disease, Lymphoma

Survival Picture No Better for Patients With HIV-Related Lymphoma: Study

Posted 26 Jul 2013 by Drugs.com

FRIDAY, July 26 – Survival rates for patients with HIV-associated lymphoma have not improved since antiretroviral therapy (ART) became available, according to a new study. HIV, the AIDS-causing virus, raises the risk of lymphoma, a blood cancer, which is the most common cancer-related cause of death among people with HIV. "These results highlight an ongoing need to ... optimize treatments for this challenging population to reduce deaths from one of the leading causes of mortality in the [antiretroviral therapy] era," said Dr. Satish Gopal, of the Lineberger Comprehensive Cancer Center at the University of North Carolina. For the study, published July 26 in the Journal of the National Cancer Institute, researchers examined data from nearly 500 patients diagnosed with HIV-associated lymphoma between 1996 and 2010. Patients diagnosed more recently were older and more likely to be male, ... Read more

Related support groups: HIV Infection, Lymphoma

FDA Approves Revlimid (lenalidomide) for the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma

Posted 5 Jun 2013 by Drugs.com

SUMMIT, N.J.--(BUSINESS WIRE)--Jun. 5, 2013-- Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental new drug application (sNDA) for Revlimid (lenalidomide) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. “There remains a tremendous unmet need for patients with previously-treated mantle cell lymphoma,” said Andre Goy, M.D., M.S., Chairman and Director and Chief of Lymphoma, John Theurer Cancer Center at Hackensack UMC and Chief Science Officer and Director of Research and Innovation at Regional Cancer Care Associates, LLC. “The approval of lenalidomide delivers a new option, and the first oral therapy in this area of lymphoma.” The approval was based on the results of MCL-001, a phase II, multi-center, singl ... Read more

Related support groups: Lymphoma, Revlimid, Lenalidomide, Lymphoma, Non-Hodgkin's

New Strategy Helps Young Lymphoma Patients Avoid Radiation Treatment

Posted 10 Apr 2013 by Drugs.com

WEDNESDAY, April 10 – A new treatment approach may mean that young people with a form of lymphoma can go without radiation therapy, sparing them side effects or raised cancer risks down the road. In a trial conducted by the U.S. National Cancer Institute, nearly all patients with a form of cancer known as primary mediastinal B-cell lymphoma who received chemotherapy, but did not undergo chest radiation, achieved a full remission. Standard treatment for this cancer typically includes radiation to the chest, the study authors pointed out, but this has been linked to significant harmful effects in the future, particularly for women. "These results are exciting and demonstrate that, using this approach, almost all patients appear to be cured and very few patients require radiation," study co-author Dr. Kieron Dunleavy, of the U.S. National Cancer Institute, said in an agency news release. ... Read more

Related support groups: Lymphoma, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma

Blood Cancer Patients May Benefit From New Transplant Technique

Posted 12 Dec 2012 by Drugs.com

WEDNESDAY, Dec. 12 – Researchers who have multiplied umbilical cord-blood cells in the laboratory say their technique might improve recovery for patients needing blood stem cell transplants to treat a blood cancer. Their approach, still in the experimental stage, involves expanding normal blood cells from donated cord blood in conditions similar to those in bone marrow. This greatly enlarges the supply needed for transplant. And because umbilical cord blood is more easily matched in patients than donor bone marrow, the recovery period is safer and shorter, the researchers said. "Since our very first patients, we had a very strong signal [of success]," said Dr. Marcos de Lima, who led the study while at the University of Texas M.D. Anderson Cancer Center in Houston. "Recipients of cord-blood transplants are less likely to have some of the complications with the same degree of matching ... Read more

Related support groups: Leukemia, Lymphoma, Multiple Myeloma

Melanoma Odds Doubled for Transplant, Lymphoma Patients: Study

Posted 10 Oct 2012 by Drugs.com

WEDNESDAY, Oct. 10 – Transplant recipients and patients with lymphoma have a significantly increased risk of developing and dying from melanoma, the most dangerous type of skin cancer, a new study indicates. Researchers from the Mayo Clinic in Minnesota found that melanoma is 2.5 times more likely to strike these patients than people in the general population. Melanoma is also more likely to be fatal in these patients, according to the study, published in the October issue of Mayo Clinic Proceedings. Patients with a form of lymphoma called chronic lymphocytic leukemia who develop melanoma are 2.8 times more likely to die from metastatic melanoma, in which the cancer spreads from the skin to other parts of the body. Transplant recipients and lymphoma patients have weakened immune systems, which makes early detection of melanoma especially important, the researchers said. Early detection ... Read more

Related support groups: Lymphoma, Melanoma

Page 1 2 Next

Ask a Question

Further Information

Related Condition Support Groups

Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Blood Disorders

Related Drug Support Groups

prednisone, methotrexate, cortisone, dexamethasone, Decadron, Velcade, Leukeran, Adriamycin, doxorubicin, view more... Deltasone, vinblastine, interferon alfa-2a, Sterapred, chlorambucil, Velban, bortezomib, Adcetris, Methotrexate LPF Sodium, Dexpak Taperpak, Sterapred DS, Liquid Pred, Adrenocot, Folotyn, Ontak, Trexall, nelarabine, thiotepa, Roferon-A, denileukin diftitox, Prednicen-M, Orasone, Meticorten, Prednicot, Tepadina, Dexamethasone Intensol, Baycadron, Adriamycin PFS, Decaject, Dalalone, Cortone Acetate, Thioplex, De-Sone LA, Decadron-LA, Solurex LA, Dexacen-4, Hexadrol, Folex PFS, pralatrexate, brentuximab, Arranon, Solurex, Dexacort-LA, Dexacorten, Medidex, Medidex LA, Primethasone, Dexone LA, Dexasone, Dexasone LA, Dexone, Adriamycin RDF